Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6625406 | 1.00 | CHRNB2 (0.61) | CHRNB2CHRNA4 | |
| SCHEMBL5034127 | 1.00 | CHRNB2 (0.61) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL7250231 | 0.98 | CHRNB2 (0.59) | CHRNB2CHRNA4 | |
| SCHEMBL5043529 | 0.87 | CHRNB2 (0.54) | CHRNB2CHRNA4 | |
| SCHEMBL5034061 | 0.83 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL5036717 | 0.83 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL20038439 | 0.82 | CHRNB2 (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL18291307 | 0.82 | CHRNB2 (0.59) | CHRNB2CHRNA4 | |
| SCHEMBL18291726 | 0.82 | CHRNB2 (0.59) | CHRNB2CHRNA4 | |
| SCHEMBL7690304 | 0.79 | CHRNB2 (0.64) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265115-B2 | Diazabicyclic CNS active agents | ABBOTT LABORATORIES (US) | 2007-09-04 | — | — | US | claimed |
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | claimed |
| EP-1147112-B1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LAB (US) | 2003-10-29 | — | — | EP | claimed |
| US-6440970-B1 | ACTIVATING NICOTINIC CHOLERGINIC RECEPTORS | TARGACEPT, INC. | 2002-08-27 | — | — | US | claimed |
| US-RE41439-E1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7265115-B2 | Diazabicyclic CNS active agents | ABBOTT LABORATORIES (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1289996-B1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6852721-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030225268-A1 | Diazabicyclic CNS active agents | ABBVIE INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1359152-A2 | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands | ABBOTT LABORATORIES (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1147112-B1 | DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ABBOTT LAB (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1289996-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | Targacept, Inc. (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6440970-B1 | ACTIVATING NICOTINIC CHOLERGINIC RECEPTORS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6440970-B1 | ACTIVATING NICOTINIC CHOLERGINIC RECEPTORS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001090109-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225268-A1 | Diazabicyclic CNS active agents | GABRE, GRIN1, CNTN1 | CHRNB2 29/4885CHRNA4 14/4885 |
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | CYP2D6, CYP3A5, CYP2B6 | CHRNB2 359/4885CHRNA4 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.